WASHINGTON (Reuters) - The U.S. House Oversight and Reform Committee has questioned four companies over their plans to use a tax provision passed in a COVID-19-related law to address their litigation costs tied to their role in the nation’s opioid crisis, it said in a statement on Friday. The panel sent letters to Cardinal Health, McKesson Corporation, AmerisourceBergen, and Johnson & Johnson seeking further related information, the statement said.